Shasun Pharmaceuticals Limited (Formerly known as 'Shasun Chemicals and Drugs Ltd.,') was incorporated in 1976 and is headquartered in Chennai, India. It manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R & D Expertise, regulatory capabilities and multi scale production capacities. Shasun has also emerged as a key player in various service segments in the pharmaceutical field besides APIs and intermediaries, and is strengthening its offer of contract research, custom synthesis, contract manufacturing and contract formulation services to clients.
Today, Shasun is one of the largest producers of Ibuprofen worldwide. The company offers derivatives of Ibuprofen like Ibuprofen Sodium, Ibuprofen Lysinate and S+Ibuprofen. It is also one of the major producers of Ranitidine and Nizatidine in the world. Its products are exported to countries across North America, Europe, Asia and Latin America.
Shasun in its endeavour to become a true one-stop shop for global pharma companies, is evolving its business model to become a complete service provider, offering services right from the discovery stage to manufacturing formulations. The company has recently added finished formulations capability as forward integration, and has invested in large facility to cater to the international regulated market. It has tied up with multinational companies in the formulations space wherein it will be developing and supplying products for the US market. The recent acquisition of the business and facilities of Rhodia Pharma Solutions by Shasun's wholly owned subsidiary Shasun Pharma Solutions Ltd (SPSL), UK equipped the company to evolve as a technology based service provider than as a contract manufacturing and research provider. Its services include innovative process research and development, rapid response small scale manufacture for clinical trial supply and full scale commercial manufacture of advanced intermediates and API's, all with seamless technology transfer with and without cGMP. The formulation unit at Puducherry has been approved by US FDA.
Recent Awards and Recognitions
Best EOU Award
Shasun Pharamaceuitcals Ltd Chennai has been given award for best EOU (MSME: (Chemical & Allied Products, Drugs, Pharmaceuticals & Allied Products) by Shri. Jyotiraditya M.Scindia, Hon'ble Minister of State for Commerce & Industry on 17th May, 2012 at NewDelhi for their outstanding export performance for the year 2009-10.
We are delighted to announce that Shasun has won the UK North East Process Industry Cluster (NEPIC) 2012 Award for innovation. This award was made to Shasun as a result of the successful development and scale up of a new route to the pharmaceutical substance (-)-Huperzine A. The award is particularly pleasing as this is the second time in a row that Shasun has won (having won the award in 2011 for the development of the 4th Generation HKR catalyst) and is a recognition of the cooperative effort of the Shasun development teams in India and UK (under the direction of Dr. Saiganesh and Dr. Ardakani). We expect to have this work published early in 2012 in the American
Chemical Society publication Organic Process Research and Development (OPRD).